KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Research & Development (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Research & Development for 17 consecutive years, with $70.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 11.68% to $70.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $275.6 million through Dec 2025, down 6.86% year-over-year, with the annual reading at $275.6 million for FY2025, 6.86% down from the prior year.
  • Research & Development for Q4 2025 was $70.3 million at Bio-Rad Laboratories, down from $71.3 million in the prior quarter.
  • The five-year high for Research & Development was $91.0 million in Q3 2024, with the low at $43.5 million in Q3 2023.
  • Average Research & Development over 5 years is $66.8 million, with a median of $65.6 million recorded in 2022.
  • The sharpest move saw Research & Development tumbled 34.84% in 2023, then skyrocketed 109.03% in 2024.
  • Over 5 years, Research & Development stood at $58.9 million in 2021, then rose by 12.5% to $66.2 million in 2022, then fell by 3.53% to $63.9 million in 2023, then rose by 24.62% to $79.6 million in 2024, then dropped by 11.68% to $70.3 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $70.3 million, $71.3 million, and $60.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.